Downloads: 113

Files in This Item:
File Description SizeFormat 
journal.pone.0169588.pdf1.53 MBAdobe PDFView/Open
Title: Time-dependent structural alteration of rituximab analyzed by LC/TOF-MS after a systemic administration to rats
Authors: Otani, Yuki
Yonezawa, Atushi
Tsuda, Masahiro  kyouindb  KAKEN_id  orcid (unconfirmed)
Imai, Satoshi  kyouindb  KAKEN_id
Ikemi, Yasuaki
Nakagawa, Shunsaku  kyouindb  KAKEN_id
Omura, Tomohiro  kyouindb  KAKEN_id
Nakagawa, Takayuki  kyouindb  KAKEN_id  orcid (unconfirmed)
Yano, Ikuko
Matsubara, Kazuo  kyouindb  KAKEN_id
Author's alias: 津田, 真弘
大村, 友博
中川, 隆之
Issue Date: 4-Jan-2017
Publisher: Public Library of Science
Journal title: PLOS ONE
Volume: 12
Issue: 1
Thesis number: e0169588
Abstract: Therapeutic monoclonal antibodies (mAbs) have heterogeneities in their structures. Multiple studies have reported that the variety of post-translational modifications could affect the pharmacokinetic profiles or pharmacological potencies of therapeutic mAbs. Taking into the account that the structural modification of mAbs would affect the efficacy, it is worth investigating the structural alteration of therapeutic mAbs in the blood and the relationship between their structures and pharmacological effects. Herein, we have developed the method to isolate rituximab from plasma in which endogenous IgGs interfere the detection of rituximab, and successfully developed the analytical method with a liquid chromatograph time-of-flight mass spectrometer to detect the structure of rituximab in plasma with errors less than 30 parts per millions. Eight types of carbohydrate chains in rituximab were detected by this method. Interestingly, time-dependent changes in carbohydrate chains such as AAF (G2F) and GnGn (G0) were observed in rats, although the amino acids were stable. Additionally, these structural changes were observed via incubation in plasma as in the rat experiment, suggesting that a certain type of enzyme in plasma caused the alterations of the carbohydrate chains. The present analytical methods could clarify the actual pharmacokinetics of therapeutic mAbs, and help to evaluate the interindividual variations in pharmacokinetics and efficacy.
Rights: © 2017 Otani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI(Published Version): 10.1371/journal.pone.0169588
PubMed ID: 28052138
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.